TP53 and breast cancer: In breast cancer cells, oncogenic mutant p53 acts as a positive transcriptional cofactor for SREBPs, leading to elevated expression of mevalonate enzymes [21] and SREBP-mevalonate axis is a relevant input for YAP/TAZ oncogenic activity [23].